Archimedean Corporation assumes significant control over Arkstone, a strategic move to intensify worldwide healthcare advancements and assert dominance within the rapidly expanding artificial intelligence-based clinical decision support industry.
In a significant move to combat antibiotic resistance and democratize infectious disease expertise, biotechnology company Arkstone has been acquired by global healthcare private equity firm ARCHIMED.
Based in the United States and internationally recognized, Arkstone specializes in machine learning and AI-driven clinical decision support for infectious diseases. Their flagship product, the OneChoice Report, is already in use by laboratories across the country and beyond.
The OneChoice Report leverages human-in-the-loop ML and AI to generate optimal infectious disease treatment recommendations, empowering clinicians to prescribe with precision and confidence. This tool democratizes infectious disease expertise, making it accessible to more clinicians worldwide.
Arkstone's mission to empower clinicians, protect patients, and lead the future of precision-guided infectious disease clinical decision support aligns perfectly with ARCHIMED's focus on antimicrobial stewardship. The partnership underscores the critical importance of this issue and positions Arkstone as a global leader at the intersection of AI, infectious disease, and clinical decision support.
Igor Petricca, Partner at ARCHIMED, commented on the partnership, stating that it will enable Arkstone to reach more markets, accelerate product innovation, and save lives by reducing the misuse of antibiotics. Ari Frenkel, Chief Science Officer and Co-Founder of Arkstone, added that the partnership ensures they have the resources, network, and strategic guidance to deliver their vision globally.
Following the acquisition, Arkstone will continue to operate with its existing team. The next phase for the company will focus on rapid growth, further product development, and entry into new markets. With ARCHIMED's support, Arkstone is poised to expand its global footprint, deepen its R&D capabilities, and bring its precision-guided technology to more clinicians around the world.
For media inquiries, Sol Levi, the media contact for Arkstone, can be reached at 1-833-933-932-753, [email protected], or www.arkstone.ai. Arkstone's website is www.arkstone.ai.
The acquisition in July 2025 by Permira, another global healthcare private equity firm, had already positioned Arkstone to make this next step. With ARCHIMED's support, Arkstone is set to revolutionize the field of infectious disease treatment and clinical decision support.
Read also:
- Europe's mandatory vaccination programs advocated by health officials in the face of mounting disinformation
- Rural farm communities sound the alarm over the perilous state of livestock deliveries
- Initial Nutrient for Boosting Immune System: Reasoning Behind Blueberries Being an Ideal First Food for Infants
- EU's ban on bean exports from Nigeria results in an annual loss of $363 million for the country, according to AAPN.
